Guangzhou LBP Medicine Science & Technology Co., Ltd.

Shanghai Stock Exchange 688393.SS

Guangzhou LBP Medicine Science & Technology Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: 39.35

Guangzhou LBP Medicine Science & Technology Co., Ltd. Price to Earnings Ratio (P/E) is 39.35 on January 14, 2025, a -24.02% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Guangzhou LBP Medicine Science & Technology Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 328.37 on December 20, 2024, which is 734.53% above the current Price to Earnings Ratio (P/E).
  • Guangzhou LBP Medicine Science & Technology Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 28.68 on February 07, 2024, which is -27.10% below the current Price to Earnings Ratio (P/E).
  • Guangzhou LBP Medicine Science & Technology Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 39.82.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
Shanghai Stock Exchange: 688393.SS

Guangzhou LBP Medicine Science & Technology Co., Ltd.

CEO Mr. Xiangting Cai
IPO Date Aug. 20, 2020
Location China
Headquarters Building 7
Employees 907
Sector Health Care
Industries
Description

Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China. It offers pathological diagnostic reagents and ancillary equipment, including liquid-based cytology, such as gynecological series, non-gynecological series, and equipment; fluorescence in situ hybridization products for various applications in breast, bladder, lung, cervical, prostate, and thyroid cancer; and neuroblastoma, soft tissue sarcoma, other solid tumors, prenatal screening and abortion, oligodendrocytes tumor, lymphoma, multiple myeloma, chronic myelogenous and lymphocytic leukemia, myelodysplastic syndromes, acute myeloid leukemia, and acute lymphoblastic leukemia. The company also provides immunohistochemistry products, which comprise antibodies, detection systems, repair systems, complementary products, and immunohistochemistry kit, as well as molecular genetic diagnosis products. Guangzhou LBP Medicine Science & Technology Co., Ltd. was founded in 2005 and is based in Guangzhou, China.

Similar companies

688338.SS

Beijing Succeeder Technology Inc.

USD 3.27

2.18%

688580.SS

Nanjing Vishee Medical Technology Co., Ltd

USD 3.72

5.33%

688108.SS

Sino Medical Sciences Technology Inc.

USD 1.31

3.77%

688026.SS

Guangzhou Jet Bio-Filtration Co., Ltd.

USD 1.70

4.79%

688085.SS

Shanghai Sanyou Medical Co., Ltd.

USD 2.79

4.08%

StockViz Staff

January 15, 2025

Any question? Send us an email